Payment overview · 2025
General Payments
$383.59
21 reported records · 11 companies
Healthcare provider profile · identity verified
Ratnakumar S Newton, MD
Allopathic & Osteopathic Physicians|Family Medicine · BUFFALO, NY · NPI 1215929658
Verified facts
What the public records show
CMS Open Payments records show Ratnakumar S Newton, MD received $383.59 in general payments during 2025 across 21 reported records.
Lilly USA, LLC accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $94.38 | 24.6% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.58 | 15.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.86 | 13.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.54 | 10.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.21 | 8.7% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $23.12 | 6.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.41 | 5.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.52 | 4.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.21 | 4.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.51 | 4.3% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $14.25 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $345.05 | 20 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $94.38 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $94.38 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.58 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $57.06 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.16 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.16 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.21 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
113 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Quetiapine Fumarate | Quetiapine Fumarate | 186 | 19 |
| Atorvastatin Calcium | Atorvastatin Calcium | 185 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 162 | 26 |
| Furosemide | Furosemide | 138 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 136 | 24 |
| Trazodone Hcl | Trazodone Hcl | 136 | 27 |
| Donepezil Hcl | Donepezil Hcl | 122 | 17 |
| Sertraline Hcl | Sertraline Hcl | 122 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 20 |
| Omeprazole | Omeprazole | 112 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 29 |
| Lisinopril | Lisinopril | 110 | 19 |
| Metformin Hcl | Metformin Hcl | 106 | 20 |
| Meloxicam | Meloxicam | 99 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 18 |
| Mirtazapine | Mirtazapine | 87 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 12 |
| Cefuroxime | Cefuroxime Axetil | 74 | 36 |
| Memantine Hcl | Memantine Hcl | 71 | 11 |
| Tramadol Hcl | Tramadol Hcl | 71 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 13 |
| Telmisartan | Telmisartan | 66 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 16 |
| Eliquis | Apixaban | 62 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 13 |
| Jardiance | Empagliflozin | 62 | 12 |
| Gabapentin | Gabapentin | 61 | 14 |
| Buspirone Hcl | Buspirone Hcl | 56 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 17 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Allopurinol | Allopurinol | 49 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 49 | suppressed |
| Spironolactone | Spironolactone | 49 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | suppressed |
| Nystatin | Nystatin | 46 | 16 |
| Losartan Potassium | Losartan Potassium | 44 | suppressed |
| Ozempic | Semaglutide | 41 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 14 |
| Potassium Chloride | Potassium Chloride | 40 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 36 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 21 |
| Ibandronate Sodium | Ibandronate Sodium | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 24 |
| Amoxicillin | Amoxicillin | 29 | 14 |
| Prednisone | Prednisone | 29 | 13 |
| Alprazolam | Alprazolam | 28 | 12 |
| Desloratadine | Desloratadine | 28 | 11 |
| Lorazepam | Lorazepam | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 14 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tri-Linyah | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $383.59 · 21 records | Lilly USA, LLC | CAPLYTA, FREESTYLE LIBRE 2, Flector, Korlym, Licart, MOUNJARO, Omnipod, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, Tirosint, UBRELVY, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error